Cargando…

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results

INTRODUCTION: The phase II JO25567 study compared the efficacy and safety of erlotinib plus bevacizumab vs. erlotinib alone as first-line therapy for advanced epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). OBJECTIVE: Our objective is to provide updated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Terufumi, Seto, Takashi, Nishio, Makoto, Goto, Koichi, Yamamoto, Noboru, Okamoto, Isamu, Tao, Liang, Yu, Wei, Khaznadar, Tarik, Tajima, Kosei, Shibata, Masahiko, Seki, Akihiro, Yamamoto, Nobuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808045/ https://www.ncbi.nlm.nih.gov/pubmed/29043496 http://dx.doi.org/10.1007/s40264-017-0596-0

Ejemplares similares

Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR(+) non-small-cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2023)

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study
por: Hosomi, Yukio, et al.
Publicado: (2022)

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer
por: Yamamoto, Noboru, et al.
Publicado: (2016)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
por: Nishio, Kazuto, et al.
Publicado: (2021)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

Jo Coenen
Publicado: (1995)

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
por: Kato, Terufumi, et al.
Publicado: (2015)

Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
por: Azuma, Koichi, et al.
Publicado: (2016)

On the groups JO(G)
por: Lee, Chung-Nim, et al.
Publicado: (1975)

I JoY
por: Nagendra, H R
Publicado: (2008)

Jo, la teva mare
por: Collange, Christiane
Publicado: (1985)

JoS now linked to PMC
por: Kim, Jong S.
Publicado: (2013)

Bevacizumab for non‐small‐cell lung cancer: A nested case control study of risk factors for hemoptysis
por: Goto, Koichi, et al.
Publicado: (2016)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
por: Seto, Takashi, et al.
Publicado: (2022)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression
por: Li, Heyan, et al.
Publicado: (2014)

Little Women, or, Meg, Jo, Beth, and Amy /
por: Alcott, Louisa May, 1832-1888
Publicado: (1915)

Little women or Meg, Jo, Beth, and My /
por: Alcott, Louisa May, 1832-1888
Publicado: (1890)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells
por: Nishidate, Masanobu, et al.
Publicado: (2017)

The First Neurologist in Korea: Dr. Succ-Jo Suh
por: Kim, Boosung
Publicado: (2015)

Journal of Stroke (JoS) Receives High Impact Factor
por: Kim, Jong S.
Publicado: (2016)

Dysphagia as Isolated Manifestation of Jo-1 Associated Myositis?
por: Labeit, Bendix, et al.
Publicado: (2019)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer
por: Nakagawa, Kazuhiko, et al.
Publicado: (2021)

Reliability of the Masada and Jo classifications for multiple hereditary exostoses in the forearm
por: Farr, Sebastian, et al.
Publicado: (2020)

COVID-19 vaccination-associated anti-Jo-1 syndrome
por: Gupta, Kushagra, et al.
Publicado: (2021)

JoGH policy on the use of artificial intelligence in scholarly manuscripts
por: Marušić, Ana
Publicado: (2023)

Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies
por: Fernandes-Cerqueira, Cátia, et al.
Publicado: (2018)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
por: Kaseb, Ahmed O, et al.
Publicado: (2016)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Are there differences in arthroscopic and histological features between traumatic and degenerative rotator cuff tears in elderly patients? A prospective dual-center analysis
por: Shibata, Terufumi, et al.
Publicado: (2022)

A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer
por: Sugiyama, Toru, et al.
Publicado: (2017)

Anti Jo-1 myositis. 'Mechanic's hands' and interstitial lung disease.
por: Taggart, A. J., et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_nkj7np2haa08356j230ulmincj